Searchable abstracts of presentations at key conferences in endocrinology

ea0029p143 | Bone & Osteoporosis | ICEECE2012

Glucocorticoid - treatment in the adrogenital syndrome due to deficit of 21-hydroxylase: long-term bone side effects

Camozzi V. , Scaroni C. , De Toni P. , Albiger N. , Zaninotto M. , Mantero F. , Luisetto G.

The purpose of this study was to compare bone mineral density (BMD) and bone metabolism in patients suffering from adrogenital syndrome due to deficit of 21-hydroxylase with those of a group of healthy subjects. A longitudinal follow-up was also carried out in a subgroup of patients.Thirty-eight patients 19-47 years old were compared with a group of healthy, age- and sex-matched controls. Sodium, potassium, calcium, phosphorus, parathyroid hormone (PTH),...

ea0029p138 | Bone & Osteoporosis | ICEECE2012

Vertebral fracture risk and bone metabolism in patients with addison’s disease

Camozzi V. , Betterle C. , De Caneva E. , Lucato P. , Piccolo M. , Zaninotto M. , Silvia G. , Rizzati S. , Mantero F. , Luisetto G.

Forty seven patients suffering from Addison’s disease (AD: 12 males and 35 females, 44.5±12.7 year old) were compared with 63 normal age-, sex- and BMI-matched subjects.The duration of disease ranged from 0.6 to 44 years (10.23±9.07 years). AD had received a cumulative dose of cortisone acetate of 290.5±326.8 g, equivalent to a daily dose of 44.5±15.5 mg, and to 26.34±10.57 mg/m2 of body surface. AD had average va...